Actualités

Trump said the new “state-of-the-art” facility would create over 1,000 jobs.

Illumina, Inc. recently expanded its Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., Chief Scientific and Product Officer at Eli Lilly and President of Lilly Research Laboratories, as an independent director effective June 16, 2026. His background in drug discovery, clinical development, and precision medicine across cardiometabolic, immunology, and neuroscience fields aligns closely with Illumina’s push into clinical genomics and multiomics. We’ll now examine...

The rally reflects broader positive sentiment toward Viking’s lead candidate, VK2735, a dual GLP-1/GIP receptor agonist being developed in both injectable and oral forms for obesity.

Lilly's expected global sales of $137 billion in 2032 will be driven by its weight-loss drugs.

The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.

Before its fifty percent surge, the drug giant was repeatedly telling a story about its future that the market seemed to be ignoring.

Eli Lilly and Company (NYSE:LLY) is among the Best Pharmaceutical Stocks. On June 5, Eli Lilly and Company (NYSE:LLY) CEO David Ricks said on The Prof G Pod that GLP-1 drugs “will turn out to be a more transformative technology than artificial intelligence.” He called artificial intelligence “overhyped” and GLP-1s “underhyped,” according to the interview. Ricks […]

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.4% and the State S

BioNeMo Agent Toolkit launches with more than 50 adopters including Anthropic, OpenAI, Eli Lilly

When Dave Ricks became chief executive officer of Eli Lilly & Co. in 2017, he was facing an industry under siege. Americans held drug companies in lower esteem than airlines, law firms and even the federal government. President Donald Trump, then starting his first term, was excoriating them for their high prices. A mounting number of reports showed that soaring costs were even forcing some diabetics to ration insulin. Ricks, the 11th CEO in Lilly's 150-year history, concedes that one was a public-relations nightmare. Almost a decade later, the mood at Lilly has shifted dramatically. The company's hit diabetes shot, Mounjaro, and obesity shot, Zepbound, have transformed its fortunes and, in many ways, its public image. We speak with Madison Muller, Bloomberg News Healthcare Reporter, for a closer look.

Report says FDA and Lilly allowed one patient to receive experimental obesity treatment retatrutide.

The GLP-1 drug market is massive and still growing fast. Investing in a promising growth stock in the space could lead to significant returns.

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

BioArctic will create a new drug candidate using its BrainTransporter platform and Lilly’s molecule.

They look well-positioned to grab a slice of the fast-growing anti-obesity market.

Eli Lilly (NYSE:LLY) has entered a partnership with BioArctic to develop a new neurodegeneration therapy using BrainTransporter drug delivery technology. The collaboration focuses on treatments that aim to cross the blood brain barrier more effectively for neurodegenerative diseases. This is BioArctic's fourth partnership using BrainTransporter, highlighting growing interest in this platform. Alongside the partnership, Eli Lilly has been active in acquisitions across neuroscience, oncology,...

Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.

Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE) just delivered Q1 2026 results that read like two different chapters of the same drug industry. Lilly is sprinting through an obesity gold rush. Pfizer is rebuilding after COVID and buying its way into the same race. Both beat estimates, but the businesses underneath could not feel ... Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow

While Wall Street fretted over the future of its biggest blockbuster, a pair of new drugs were already showing the company's next act was well underway.

AbbVie will acquire the clinical-stage biotech’s pipeline of candidates for inflammatory and immunological diseases.

ABBV's successful transition beyond Humira and growth from newer medicines give it an edge over MRK in this oncology-immunology showdown.

With a short percentage of shares outstanding of 1.10%, Eli Lilly and Company (NYSE:LLY) is among the 7 Best Longevity and Anti-Aging Stocks to Buy. On June 16, Austin-based neuroscience company 4E Therapeutics announced that it had been acquired by Eli Lilly and Company (NYSE:LLY). 4E Therapeutics is developing a pipeline of orally available MNK inhibitors designed […]

AbbVie will acquire the clinical-stage biotech’s pipeline of candidates for inflammatory and immunological diseases.

Houman Ashrafian is leaving Sanofi to pursue a new opportunity. Elsewhere, one of Merck’s prized immune drugs succeeded in a pivotal study and a psychedelics biotech’s shares surged.

Doctors are looking for better options given the growing awareness of the serious health risks tied to childhood obesity.

SK Hynix has surpassed Samsung Electronics in market cap for the first time since 2000, now worth more than Bitcoin at $1.35 trillion.

The Health Care Select Sector SPDR ETF (NYSEARCA:XLV) is having a frustrating year. The fund sits at $149, down about 3% year-to-date while the broader market grinds higher. The good news for XLV holders: the fund has clawed back roughly 14% over the past year, and the 2026 setup looks meaningfully different from the policy ... The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026

If you are wondering whether Eli Lilly stock is still worth considering at its current level, the key question is how its price lines up with the underlying value of the business. The share price most recently closed at US$1,098.57, with returns of 5.5% over the past month and 45.1% over the past year, while also showing a decline of 3.0% over the last week and a modest 1.7% gain year to date. Recent coverage of Eli Lilly has focused on its position as a major pharmaceutical company and the...

Pfizer is out of favor right now, and for good reason, but dividend investors may want to take the risk just the same.

Novo Nordisk has been telling investors that volume will eventually offset price cuts, and early results suggest investors should listen.